Highlights and video from the poster
presentation made at ASCO 2010
Provectus
Updates Shareholders on 2009 Year-to-date Accomplishments
Progress Made In Therapies for Metastatic
Melanoma, Atopic Dermatitis and Psoriasis
Highlights and video from the poster
presentation made at ASCO 2009
6th
International Symposium on Melanoma and Other Cutaneous Malignancies
Professor John F. Thompson,M.D. presentated interim results of the phase 2 clinical trial of PV-10 for melanoma in March 2009.
Perspectives
In Melanoma Conference XII Presentation
Professor John F. Thompson,M.D. presented
interim results of Phase 2 PV-10 for melanoma trial in October 2008.
PV-10
for Melanoma Story Airs in Australia
Video interviews with Professor John
Thompson and a patient who was involved in the Phase 2 study of PV-10
for melanoma.
Professor John Thompson of the Sydney
Melanoma Unit presents preliminary findings from Phase 2 study of PV-10
for melanoma.
30 second preview of Provectus' multimedia annual report.
Clinical trial information at ClinicalTrials.gov
Summary of the clinical effects of PV-10 on melanoma
Melanoma Research Publishes PV-10 Article
[video] PV-10 for melanoma story airs on Australian TV
Information on the Compassionate Use Program for PV-10
Subscribe to the Provectus News newsletter
Opening
a New Front in the
War Against Cancer
Provectus Pharmaceuticals is developing advanced therapies designed to:
Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.
For further information, read our detailed Research Reports.
Legal Notice ©2002-2010 Provectus Pharmaceuticals, Inc.
An article, entitled "Knox company enters clinical trial stage for cancer drug", appearing in the Knoxville News Sentinel, highlights Provectus' preparation for a Phase 3 trial of PV-10 for metastatic melanoma.
August 9, 2010An article on PV-10 for metastatic melanoma was published in the July 2010 edition of Cancerwatch.
July 19, 2010An article on Ipilimumab appearing in Oncology NEWS International contains a sidebar on PV-10 for metastatic melanoma
July 8, 2010A news brief appearing in HemOnc Today titled "Rose bengal active in metastatic melanoma" briefly summarizes positive results from the Phase 2 clinical trial of PV-10 for metastatic melanoma.
July 7, 2010In an article titled "Promising Data on Ipilimumab and Other Investigational Melanoma Therapies", appearing in the July 2010 issue of Practical Dermatology, Jonathan Wolfe, MD discusses promising findings on potential new treatments for advanced melanoma, including PV-10.
June 10, 2010Doctor's Guide published an article 06.09.2010 titled "Chemoablation of Metastatic Melanoma with Rose Bengal Shows Robust Response: Presented at ASCO" reporting on the Phase 2 PV-10 for metastatic melanoma clinical data presented at ASCO 2010 by lead investigator Sanjiv Agarwala, MD.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) will present at the Rodman & Renshaw 12th Annual Healthcare Conference in New York City on September 14, 2010 at 3:15 p.m. Eastern Time. The conference will be held at the New York Palace Hotel.
Read the complete article here.
July 27, 2010KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has signed an agreement with Numoda Capital Innovations LLC (http://www.numodacapital.com) to license its TruPoints strategic partnering platform.
Read the complete article here.
July 15, 2010KNOXVILLE, Tenn., July 15 --(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) reports on its first half 2010 clinical and corporate accomplishments, as well as its clinical development plans, in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus.
Read the complete article here.
June 07, 2010KNOXVILLE, Tenn., June 7 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr. Sanjiv Agarwala at the American Society of Clinical Oncology 2010 Annual Meeting, on Sunday, June 6, 2010, in the General Poster Session on Melanoma/Skin Cancers, Abstract #8534. Positive improvement observed in these remote, untreated lesions, including metastases to the lungs, liver and brain, illustrate a potential systemic effect in visceral organs to which melanoma has spread. Dr. Agarwala's updated information included data from both the initial 40 subjects and the final 40 subjects enrolled in the Phase 2 trial.
Read the complete article here.
May 21, 2010KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.
Read the complete article here.
April 29, 2010KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.
Read the complete article here.
ASCO
2010 Presentation
ASCO
2009 Presentation
SCC
2008 Presentation
Provectus
Preview